MELBOURNE, Australia — September 17, 2025 — Leads & Copy — Propanc Biopharma, Inc. (Nasdaq: PPCB) has secured a U.S. patent for its proenzyme composition from the U.S. Patent & Trademark Office (USPTO), marking the fourth U.S. patent for the company’s lead asset, PRP. The patent covers a future clinical dose of PRP. Propanc’s intellectual property portfolio includes 90 patents related to PRP’s use against solid tumors.
According to Propanc, the proenzymes composition patent is significant for a potential future clinical dose of PRP as it advances to a Phase 1B study in advanced cancer patients with solid tumors. The patent has also been granted in Europe, Japan, and Southeast Asia. Emergen Research projects the global metastatic cancer treatment market to reach US$111.2 billion by 2027.
Propanc Biopharma, Inc. is focused on preventing the recurrence and metastasis of solid tumors using pancreatic proenzymes that target cancer stem cells in pancreatic, ovarian, and colorectal cancers.
James Nathanielsz, Propanc’s Chief Executive Officer, +61-3-9882-0780, info@propanc.com
Source: Propanc Biopharma, Inc.
